Arcturus ARCT-154 Phase 3 shows 55% efficacy vs COVID-19, 95% vs severe disease

Arcturus Therapeutics Holdings Inc.

Two 5-mcg doses of ARCT-154 provided 55% efficacy (95% CI 46.9-61.9) against symptomatic COVID-19.
Vaccine demonstrated 95.3% efficacy (95% CI 80.4-98.9) against severe COVID-19 including deaths.
No cases of myocarditis or pericarditis reported; unsolicited adverse events comparable to placebo.
Data submitted to Vietnam Ministry of Health for EUA; ARCT-154 advancing to pivotal booster trial in major markets.
Also amended loan with Western Alliance Bank to extend interest-only payments to Aug 1, 2022, and terminated Israeli supply deal for first-gen vaccine (no penalty).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.